Scalper1 News
Nomura analyst Ian Somaiya raised his price targets on Pharmacyclics (PCYC) and Gilead Sciences (GILD) and lowered it on Biogen Idec (BIIB) after a survey of their competing drugs for chronic lymphocytic leukeumia. Somaiya wrote that his survey of 30 doctors treating more than 1,600 CLL patients “highlighted rapid transition of the CLL market to newer oral drugs, in particular PCYC’s Imbruvica,” which was launched by Pharmacyclics and Johnson & Scalper1 News
Scalper1 News